Compare DAKT & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAKT | PCRX |
|---|---|---|
| Founded | 1968 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.7M | 1.0B |
| IPO Year | 1996 | 2010 |
| Metric | DAKT | PCRX |
|---|---|---|
| Price | $20.12 | $23.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $30.25 |
| AVG Volume (30 Days) | 240.2K | ★ 527.9K |
| Earning Date | 03-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | ★ 0.75 | 0.07 |
| Revenue | ★ $608,932,000.00 | $541,533,000.00 |
| Revenue This Year | $12.06 | $6.78 |
| Revenue Next Year | $9.16 | $8.54 |
| P/E Ratio | ★ $26.87 | $332.14 |
| Revenue Growth | 6.89 | ★ 26.04 |
| 52 Week Low | $13.05 | $18.80 |
| 52 Week High | $28.27 | $27.64 |
| Indicator | DAKT | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.01 | 49.85 |
| Support Level | $18.99 | $22.13 |
| Resistance Level | $20.55 | $24.20 |
| Average True Range (ATR) | 0.56 | 1.02 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 64.53 | 42.93 |
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.